A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Share
Print

Full Title

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas (A051902) (CIRB)

Purpose

The purpose of this study is to compare the safety and effectiveness of adding duvelisib or CC-486 (oral azacitidine) to the usual chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) in people with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth; it is taken orally (by mouth).

Participants will be randomly assigned to receive either:

  • Duvelisib plus chemotherapy
  • CC-486 plus chemotherapy
  • Chemotherapy alone

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Participants must have peripheral T-cell lymphoma that has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please call the office of Dr. Alison Moskowitz at 646-608-3726.

Protocol

21-343

Phase

II

Investigator